IMMUNOMODULATORS IN THE TREATMENT OF ATHEROSCLEROSIS AND OTHER CHRONIC HEART DISEASES: PROSPECTS AND RISKS.
Long-term monitoring of immunosuppressive therapy safety profiles, particularly regarding infectious complications and oncological risks, remains critically important for future large-scale studies requiring decade-long surveillance in diverse populations.
Authors
- Yu. V. Tyravska
- Dmytro Maltsev (ORCID: https://orcid.org/0000-0002-6615-3072)
- Vitalyj Reshetylo (ORCID: https://orcid.org/0000-0001-6216-3524)
- V Moyseyenko
- V Yakymenko
Institutions
- Ivano-Frankivsk National Medical University (UA)
- Zaporizhzhia State Medical and Pharmaceutical University (UA)
- Bogomolets National Medical University (UA)
Publication Details
- Journal
- PubMed
- Published
- 2025-12-01
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00